Other Clinical Trial - A Safety Study Of A Monoclonal Antibody Against

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Non-Hematologic Malignancies

See also
Status	Clinical Trial	Phase
Completed	`NCT01653158` - CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies	Phase 1
Completed	`NCT00830869` - A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT00948467` - Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1

See also

Status

Clinical Trial

Phase

Completed

NCT01653158 - CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

Phase 1

Completed

NCT00830869 - A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Phase 1

Completed

NCT00948467 - Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00915278
Study type	Interventional
Source	Pfizer
Contact
Status	Terminated
Phase	Phase 1
Start date	September 2009
Completion date	January 2013

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms